Real-world cost effectiveness of first-line pembrolizumab for advanced melanoma: A population-based study by the Canadian Real-world Evidence Value for Cancer Drugs (CanREValue) Collaboration.

被引：0
|
作者：
Hanna, Timothy
Aktar, Suriya
Arciero, Vanessa
Liu, Ning
Chan, Kelvin K.
机构：
[1] Queens Univ, Canc Res Inst, Div Canc Care & Epidemiol, Kingston, ON, Canada
[2] ICES, Toronto, ON, Canada
[3] Univ Toronto, Temerty Fac Med, Toronto, ON, Canada
[4] Univ Toronto, Odette Canc Ctr, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 28期
基金：
加拿大健康研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
17
引用
收藏
页码：17 / 17
页数：1
相关论文
共 50 条
  • [21] Real-World Evidence of Ribociclib Plus Aromatase Inhibitors as First-Line Treatment in Advanced Breast Cancer: The BrasiLEEira Study
    Suzuki, Daniele Assad
    Morelle, Alessandra Menezes
    de Brito, Mayana Lopes
    Paes, Flavia Rocha
    Mattar, Andre
    Leal, Jorge H. Santos
    Simon, Sergio D.
    Lima, Ellias Magalhaes Abreu
    Werutsky, Gustavo
    Piotto, Gustavo H. Munhoz
    Bines, Jose
    Damiani, Lucas Petri
    Macedo, Ariane
    Campos, Ligia
    Buehler, Anna Maria
    JCO GLOBAL ONCOLOGY, 2024, 10
  • [22] Comparative effectiveness of antidepressants on geriatric depression: Real-world evidence from a population-based study
    Hsu, Chih-Wei
    Tseng, Wei-Ting
    Wang, Liang-Jen
    Yang, Yao-Hsu
    Kao, Hung-Yu
    Lin, Pao-Yen
    JOURNAL OF AFFECTIVE DISORDERS, 2022, 296 : 609 - 615
  • [23] A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer
    Zhan, Gouling
    Hu, Jianbing
    Da, Shijian
    Weng, Jie
    Zhou, Chuanyi
    Wen, Fang
    Liu, Songlian
    Fang, Fang
    Shen, Erdong
    Zhou, Qiang
    Luo, Pan
    Xu, Min
    Zhan, Dahe
    Su, Yuqi
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [24] Efficacy of rechallenge after first-line immunotherapy for advanced gastric cancer: A retrospective real-world study
    Guo, Mengya
    Zhao, Wenhui
    Chen, Yue
    Zou, Dan
    Peng, Weiwei
    Sha, Huanhuan
    Zhou, Guoren
    Fang, Ying
    Shen, Bo
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [25] Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study
    Santoni, Matteo
    Myint, Zin W.
    Buettner, Thomas
    Takeshita, Hideki
    Okada, Yohei
    Lam, Elaine T.
    Gilbert, Danielle
    Kueronya, Zsofia
    Tural, Deniz
    Pichler, Renate
    Grande, Enrique
    Crabb, Simon J.
    Kemp, Robert
    Massari, Francesco
    Scagliarini, Sarah
    Iacovelli, Roberto
    Vau, Nuno
    Basso, Umberto
    Maruzzo, Marco
    Molina-Cerrillo, Javier
    Galli, Luca
    Bamias, Aristotelis
    De Giorgi, Ugo
    Zucali, Paolo Andrea
    Rizzo, Mimma
    Seront, Emmanuel
    Popovic, Lazar
    Caffo, Orazio
    Buti, Sebastiano
    Kanesvaran, Ravindran
    Kopecky, Jindrich
    Kucharz, Jakub
    Zeppellini, Annalisa
    Fiala, Ondrej
    Landmesser, Johannes
    Ansari, Jawaher
    Giannatempo, Patrizia
    Rizzo, Alessandro
    Zabalza, Ignacio Ortego
    Monteiro, Fernando Sabino M.
    Battelli, Nicola
    Calabro, Fabio
    Porta, Camillo
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (09) : 2961 - 2970
  • [26] Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study
    Matteo Santoni
    Zin W. Myint
    Thomas Büttner
    Hideki Takeshita
    Yohei Okada
    Elaine T. Lam
    Danielle Gilbert
    Zsófia Küronya
    Deniz Tural
    Renate Pichler
    Enrique Grande
    Simon J. Crabb
    Robert Kemp
    Francesco Massari
    Sarah Scagliarini
    Roberto Iacovelli
    Nuno Vau
    Umberto Basso
    Marco Maruzzo
    Javier Molina-Cerrillo
    Luca Galli
    Aristotelis Bamias
    Ugo De Giorgi
    Paolo Andrea Zucali
    Mimma Rizzo
    Emmanuel Seront
    Lazar Popovic
    Orazio Caffo
    Sebastiano Buti
    Ravindran Kanesvaran
    Jindrich Kopecky
    Jakub Kucharz
    Annalisa Zeppellini
    Ondřej Fiala
    Johannes Landmesser
    Jawaher Ansari
    Patrizia Giannatempo
    Alessandro Rizzo
    Ignacio Ortego Zabalza
    Fernando Sabino M. Monteiro
    Nicola Battelli
    Fabio Calabrò
    Camillo Porta
    Cancer Immunology, Immunotherapy, 2023, 72 : 2961 - 2970
  • [27] Impact of Real-World Adherence on Effectiveness of First-Line DMTs in Multiple Sclerosis
    Agashivala, Neetu
    Raimundo, Karina
    Kim, Edward
    Brandes, David
    NEUROLOGY, 2013, 80
  • [28] "Real-world" cost for first-line treatment for prostate cancer; A comparative cost analysis in the public sector
    Hanna, Bishoy
    Reddy, Sumeet
    Jackson, Stuart
    Chia, Daniel
    Thangasamy, Isaac
    Azzi, Maria
    Ko, Raymond
    Winter, Matthew
    Khadra, Mohamed
    Arianayagam, Mohan
    Canagasingham, Bertram
    Goolam, Ahmed
    Jeffery, Nicola
    Mehan, Nicholas
    Varol, Celi
    BJU INTERNATIONAL, 2022, 129 : 133 - 133
  • [29] Real-world cost for first-line treatment for prostate cancer: A comparative cost analysis in the public sector
    Reddy, S.
    Hanna, B.
    Ferguson, R.
    Jackson, S. R.
    Rose, H.
    Chia, D.
    Azzi, M.
    Ko, R.
    Winter, M.
    Arianayagam, M.
    Canagasingham, B.
    Goolam, A.
    Jeffery, N.
    Mehan, N.
    Varol, C.
    EUROPEAN UROLOGY, 2022, 81 : S9 - S9
  • [30] Real-world time on treatment (rwToT) analysis for first-line pembrolizumab combination therapy in advanced nonsquamous NSCLC
    Liu, S. V.
    Hu, X.
    Li, Y.
    Burke, T.
    Piperdi, B.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S756 - S757
12345